logo banner home news contact





Return to Events

Evolving Standards and Future Direction for Advanced Renal Cell Carcinoma (RCC) - The Promise of Personalized Dendritic Cell Immunotherapy

November 1, 2010 at 1pm EDT

Click here to register for the Webinar: http://www.videonewswire.com/event.asp?id=73668
Also, dial in at 1-800-860-2442 or 1-412-858-4600 and reference Argos Therapeutics.


Christopher G. Wood, M.D., of The University of Texas M. D. Anderson Cancer Center, will discuss the role of cytoreductive nephrectomy in advanced RCC.

Brian I. Rini, M.D., of the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, will discuss current treatment paradigms for advanced RCC.

Robert A. Figlin, M.D., of Cedars-Sinai´s Samuel Oschin Comprehensive Cancer Institute, will discuss the future directions in advanced RCC and the role of personalized immunotherapy with an insight into Argos’ Arcelis immunotherapy for RCC, AGS-003.